{"id":832316,"date":"2025-04-01T10:27:33","date_gmt":"2025-04-01T14:27:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/"},"modified":"2025-04-01T10:27:33","modified_gmt":"2025-04-01T14:27:33","slug":"marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/","title":{"rendered":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference"},"content":{"rendered":"
\n

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) — MARKER THERAPEUTICS, INC.<\/a>\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,\u00a0today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity\u2019s Horizons in Oncology Virtual Conference.<\/a><\/p>\n

Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors.<\/p>\n

\n Panel Participation Details:<\/strong>\n <\/p>\n\n\n\n\n\n
\n Event<\/strong>\n <\/td>\nCG Horizons in Oncology Virtual Conference<\/td>\n<\/tr>\n
\n Panel Title<\/strong>\n <\/td>\nCAR-T in Solid Tumors and New T-cell Approaches \u2013 Breakthroughs Ahead?<\/td>\n<\/tr>\n
\n Date<\/strong>\n <\/td>\nMonday, April 7, 2025<\/td>\n<\/tr>\n
\n Time<\/strong>\n <\/td>\n11:00 AM \u2013 11:50 AM ET<\/td>\n<\/tr>\n<\/table>\n

\n
Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, an approach that has shown promising clinical results in hematologic malignancies and solid tumors.<\/p>\n

To join the virtual panel discussion, please contact your Canaccord Genuity conference representative.<\/p>\n

\n About\u00a0Marker Therapeutics, Inc.<\/strong>
\n
Marker Therapeutics, Inc.\u00a0is a\u00a0Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at\u00a0Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company\u2019s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker\u2019s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker\u2019s unique T cell platform is strengthened by non-dilutive funding from\u00a0U.S.\u00a0state and federal agencies supporting cancer research.<\/p>\n

To receive future press releases via email, please visit: https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n

\n Media and Investor Contact<\/strong>
\n
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) — MARKER THERAPEUTICS, INC.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,\u00a0today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity\u2019s Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: Event CG Horizons in Oncology Virtual Conference Panel Title CAR-T in Solid Tumors and New T-cell Approaches \u2013 Breakthroughs Ahead? Date Monday, April 7, 2025 Time 11:00 AM … <\/p>\n

Continue reading “Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832316","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMarker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) — MARKER THERAPEUTICS, INC.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,\u00a0today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity\u2019s Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: Event CG Horizons in Oncology Virtual Conference Panel Title CAR-T in Solid Tumors and New T-cell Approaches \u2013 Breakthroughs Ahead? Date Monday, April 7, 2025 Time 11:00 AM … Continue reading "Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-01T14:27:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference\",\"datePublished\":\"2025-04-01T14:27:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/\",\"name\":\"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=\",\"datePublished\":\"2025-04-01T14:27:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk","og_description":"HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) — MARKER THERAPEUTICS, INC.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,\u00a0today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity\u2019s Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: Event CG Horizons in Oncology Virtual Conference Panel Title CAR-T in Solid Tumors and New T-cell Approaches \u2013 Breakthroughs Ahead? Date Monday, April 7, 2025 Time 11:00 AM … Continue reading \"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-01T14:27:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference","datePublished":"2025-04-01T14:27:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/","name":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=","datePublished":"2025-04-01T14:27:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDc0NiM2ODQ1MDg0IzIxODc3MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-canaccord-genuitys-horizons-in-oncology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics to Present at Canaccord Genuity\u2019s Horizons in Oncology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832316"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832316\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}